WNT1-inducible signaling pathway protein-1 (WISP1) is a secreted matricellular protein shown to have a relevant role in fibrosis progression, making the protein a compelling target for anti-fibrosis therapeutics. MTX-463 is a first-in-class human IgG1 antibody designed to neutralize the WISP1-mediated fibrotic signaling that spans several fibrotic indications, including those in the lung and liver. A Phase 2 study of MTX-463 in patients with Idiopathic Pulmonary Fibrosis (IPF) is now recruiting (NCT06967805) and more information can be found at: wispertrial.com

EphrinB2 mediates biological processes involved in tissue fibrosis including cell migration, myofibroblast activation, and tissue remodeling. A growing body of evidence has implicated EphrinB2 in the fibrosis of the skin, lungs, and heart. MTX-474 is a first-in-class human IgG1 antibody designed to neutralize the EphrinB2 signaling that causes the onset and progression of fibrosis. A global Phase 2 study of MTX-474 in patients with Systemic Sclerosis (SSc) is now recruiting (NCT07287670) and more information can be found at encompassctrial.com

SMOC2 is a secreted matricellular protein that promotes extracellular matrix assembly, cell adhesion and kidney fibrosis. Furthermore, in human studies across fibrotic indications, SMOC2 expression levels correlate with disease severity and/or outcomes. Mediar has completed IND enabling studies and expected to start Ph-1 studies in H1-2026 in healthy volunteers and CKD patients with fibrosis.

Mediar is advancing novel bi-specific programs to further unlock validated mechanisms with our novel anti-fibrotic portfolio. We are currently advancing two bi-specific programs in Oncology & IBD indications, and considering other pairings with our first-in-class antibodies.